GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (GREY:BBAGF) » Definitions » Revenue per Share

BB Biotech AG (BB Biotech AG) Revenue per Share : $-3.55 (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is BB Biotech AG Revenue per Share?

BB Biotech AG's revenue per share for the three months ended in Dec. 2023 was $2.34. BB Biotech AG's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.55.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for BB Biotech AG's Revenue per Share or its related term are showing as below:

During the past 13 years, BB Biotech AG's highest 3-Year average Revenue Per Share Growth Rate was 114.10% per year. The lowest was -80.80% per year. And the median was 0.30% per year.

BBAGF's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

BB Biotech AG Revenue per Share Historical Data

The historical data trend for BB Biotech AG's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Revenue per Share Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.59 14.21 -7.77 -6.85 -4.21

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 -4.97 -0.09 -0.83 2.34

Competitive Comparison of BB Biotech AG's Revenue per Share

For the Biotechnology subindustry, BB Biotech AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's PS Ratio distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's PS Ratio falls into.



BB Biotech AG Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

BB Biotech AG's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-230.767/54.846
=-4.21

BB Biotech AG's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=128.55/54.846
=2.34

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BB Biotech AG  (GREY:BBAGF) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


BB Biotech AG Revenue per Share Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (BB Biotech AG) Business Description

Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (BB Biotech AG) Headlines

No Headlines